HER2
22 drugs Oncology
5
approved indications
22
Approved Drugs
16
Companies
22
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (16 companies)
✓ All 22 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (22 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Roche 5 drugs
Pfizer 2 drugs
Boehringer Ingelheim 2 drugs
By Therapeutic Area
Oncology 18 drugs
Other 4 drugs
Drugs by Company PRO
Roche 5 drugs
DAIICHI SANKYO 1 drug
AstraZeneca 1 drug
Viatris 1 drug
CELLTRION INC 1 drug
SAMSUNG BIOEPIS CO LTD 1 drug
Amgen 1 drug
SEAGEN 1 drug
+ 6 more companies
By Therapeutic Area
Oncology 18 drugs
OGIVRI, HERZUMA, ONTRUZANT, KANJINTI +14 more
Other 4 drugs
ENHERTU, TAGRISSO, HERCEPTIN, ZIIHERA
Indications Treated
Breast CancerGastric CancerGastroesophageal Junction AdenocarcinomaUnresectable or metastatic HER2-positive breast cancerUnresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancerUnresectable or metastatic HER2-low breast cancerUnresectable or metastatic HER2-mutant non-small cell lung cancerLocally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinomaNon-Small Cell Lung CancerColorectal CancerPancreatic AdenocarcinomaBiliary Tract CancerMetastatic Breast CancerEarly Breast CancerAdjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC)Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapyFirst-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLCFirst-line treatment of adult patients with locally advanced or metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC, in combination with pemetrexed and platinum-based chemotherapyMetastatic EGFR T790M mutation-positive NSCLC in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapyHER2-overexpressing adjuvant breast cancerHER2-overexpressing metastatic breast cancerHER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
All Drugs Targeting HER2
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| ENHERTU | DAIICHI SANKYO | 2019 | 5 | |
| TAGRISSO | AstraZeneca | 2015 | 5 | |
| OGIVRI | Viatris | 2017 | 3 | Oncology |
| HERZUMA | CELLTRION INC | 2018 | 3 | Oncology |
| ONTRUZANT | SAMSUNG BIOEPIS CO LTD | 2019 | 3 | Oncology |
| KANJINTI | Amgen | 2019 | 3 | Oncology |
| TRAZIMERA | Pfizer | 2019 | 3 | Oncology |
| HERCEPTIN | Roche | 1998 | 3 | |
| TUKYSA | SEAGEN | 2020 | 2 | Oncology |
| BIZENGRI | MERUS N.V. | 2024 | 2 | Oncology |
| PERJETA | Roche | 2012 | 2 | Oncology |
| PHESGO | Roche | 2020 | 2 | Oncology |
| KADCYLA | Roche | 2013 | 1 | Oncology |
| MARGENZA | MACROGENICS INC | 2020 | 1 | Oncology |
| GILOTRIF | Boehringer Ingelheim | 2013 | 1 | Oncology |
| HERNEXEOS | Boehringer Ingelheim | 2025 | 1 | Oncology |
| NERLYNX | PUMA BIOTECH | 2017 | 1 | Oncology |
| HERCEPTIN HYLECTA | Roche | 2019 | 1 | Oncology |
| ZIIHERA | JAZZ PHARMS | 2024 | 1 | |
| VIZIMPRO | Pfizer | 2018 | 1 | Oncology |
| HYRNUO | Bayer | 2025 | 1 | Oncology |
| TYKERB | Novartis | 2007 | 1 | Oncology |